A detailed history of Farther Finance Advisors, LLC transactions in Genmab A/S stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 59 shares of GMAB stock, worth $1,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59
Previous 234 74.79%
Holding current value
$1,214
Previous $5.82 Million 75.17%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$23.84 - $28.48 $4,172 - $4,984
-175 Reduced 74.79%
59 $1.44 Million
Q2 2024

Jul 31, 2024

BUY
$25.13 - $30.27 $1,558 - $1,876
62 Added 36.05%
234 $5.82 Million
Q1 2024

May 13, 2024

SELL
$26.43 - $32.77 $52 - $65
-2 Reduced 1.15%
172 $5.21 Million
Q4 2023

Feb 14, 2024

BUY
$27.94 - $35.44 $4,135 - $5,245
148 Added 569.23%
174 $5.54 Million
Q3 2023

Nov 13, 2023

BUY
$35.27 - $42.24 $917 - $1,098
26 New
26 $917,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.